X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
index medicus (11) 11
adult (10) 10
female (10) 10
male (10) 10
human immunodeficiency virus--hiv (9) 9
middle aged (9) 9
antiretroviral drugs (8) 8
drug therapy (7) 7
hiv (7) 7
hiv infection (7) 7
hiv infections - drug therapy (7) 7
antiretroviral therapy (6) 6
emtricitabine (6) 6
life sciences (6) 6
tenofovir (6) 6
treatment outcome (6) 6
viral load (6) 6
adults (5) 5
antiviral agents (5) 5
infections (5) 5
infectious diseases (5) 5
internal medicine (5) 5
medicine, general & internal (5) 5
safety (5) 5
abridged index medicus (4) 4
adenine - analogs & derivatives (4) 4
anti-hiv agents - adverse effects (4) 4
clinical trials (4) 4
deoxycytidine - analogs & derivatives (4) 4
dosage and administration (4) 4
protease inhibitors (4) 4
ritonavir (4) 4
adenine - administration & dosage (3) 3
adenine - adverse effects (3) 3
aged (3) 3
anti-hiv agents - administration & dosage (3) 3
anti-hiv agents - therapeutic use (3) 3
cd4 lymphocyte count (3) 3
cross infection (3) 3
darunavir (3) 3
deoxycytidine - administration & dosage (3) 3
deoxycytidine - adverse effects (3) 3
double-blind method (3) 3
drug combinations (3) 3
drug resistance (3) 3
efavirenz (3) 3
health aspects (3) 3
hepatitis (3) 3
hiv infections - virology (3) 3
hiv-1 (3) 3
immunology (3) 3
infectious disease (3) 3
lamivudine (3) 3
nosocomial infections (3) 3
organophosphonates - administration & dosage (3) 3
organophosphonates - adverse effects (3) 3
randomization (3) 3
ritonavir - administration & dosage (3) 3
therapy (3) 3
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (2) 2
[sdv]life sciences [q-bio] (2) 2
abacavir-lamivudine (2) 2
adenine - therapeutic use (2) 2
aids/hiv (2) 2
algorithms (2) 2
analysis (2) 2
anti-hiv agents (2) 2
benzoxazines - adverse effects (2) 2
benzoxazines - therapeutic use (2) 2
biomarkers - blood (2) 2
blood (2) 2
bone density (2) 2
bone density - drug effects (2) 2
carbamates - administration & dosage (2) 2
cobicistat (2) 2
combination (2) 2
deoxycytidine - therapeutic use (2) 2
disease (2) 2
disoproxil fumarate (2) 2
drug administration schedule (2) 2
drug therapy, combination (2) 2
efficacy (2) 2
exposure (2) 2
france (2) 2
gastroenterology & hepatology (2) 2
gastroenterology and hepatology (2) 2
hepatitis b (2) 2
hiv infections - complications (2) 2
hiv patients (2) 2
hiv-1 - isolation & purification (2) 2
hiv-1-infected patients (2) 2
human health and pathology (2) 2
infected patients (2) 2
inhibitors (2) 2
laboratories (2) 2
lipids (2) 2
liver (2) 2
markers (2) 2
medical colleges (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 4, pp. 387 - 396
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9568, pp. 1169 - 1178
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 11, pp. 1283 - 1291
Journal Article
Lancet HIV, The, ISSN 2352-3018, 2015, Volume 2, Issue 11, pp. e464 - e473
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | TREATMENT-NAIVE | PHARMACOKINETICS | RALTEGRAVIR | SAFETY | EFAVIRENZ | ADULTS | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | ADHERENCE | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems
Journal Article
by Cahn, Pedro and Madero, Juan Sierra and Arribas, José Ramón and Antinori, Andrea and Ortiz, Roberto and Clarke, Amanda E and Hung, Chien-Ching and Rockstroh, Jürgen K and Girard, Pierre-Marie and Sievers, Jörg and Man, Choy and Currie, Alexander and Underwood, Mark and Tenorio, Allan R and Pappa, Keith and Wynne, Brian and Fettiplace, Anna and Gartland, Martin and Aboud, Michael and Smith, Kimberly and Cassetti, Lidia and David, Daniel and Figueras, Laura and Losso, Marcelo and Lopardo, Gustavo and Lupo, Sergio and Porteiro, Norma and Sánchez, Marisa and Bloch, Mark and Cooper, David and Finlayson, Robert and Kelleher, Anthony and Koh, Kenneth and Lewis, David and McMahon, James and Moore, Richard and Roth, Norman and Shields, Matthew and De Wit, Stephane and Florence, Eric and Goffard, Jean-Christophe and Demeester, Remy and Lacor, Patrick and Vandercam, Bernard and Vandekerckhove, Linos and Angel, Jonathan and Baril, Jean-Guy and Conway, Brian and De Pokomandy, Alexandra and Szabo, Jason and Walmsley, Sharon and Bouchaud, Olivier and Chidiac, Christian and Delobel, Pierre and Goujard, Cecile and Katlama, Christine and Molina, Jean-Michel and Pialoux, Gilles and Philibert, Patrick and Bogner, Johannes and Esser, Stefan and Krznaric, Ivanka and Lehmann, Clara and Spinner, Christoph and Stellbrink, Hans-Jurgen and Stephan, Christoph and Stoehr, Albrecht and Barchi, Enrico and Caramello, Pietro and Castelli, Francesco and Cattelan, Anna Maria and D'Arminio Monforte, Antonella and Di Biagio, Antonio and Di Perri, Giovanni and Gori, Andrea and Maggiolo, Franco and Menzaghi, Barbara and Migliorino, Guglielmo and Mussini, Cristina and Penco, Giovanni and Puoti, Massimo and Rizzardini, Giuliano and Gulminetti, Roberto and Lazzarin, Adriano and Quirino, Tiziano and Sighinolfi, Laura and Viale, Pierluigi and Amaya Tapia, Gerardo and Andrade Villanueva, Jaime and Granados Reyes, Enrique R and Perez Rios, Alma and Santoscoy Gomez, Mario and Den Hollander, Jan and Rijnders, Bart and Hidalgo, José A and Hercilla Vasquez, Luis and Illescas, Luis and Olczak, Anita and Mansinho, Kamal and Correia Pacheco, Patricia Paula and ... and GEMINI Study Team
The Lancet, ISSN 0140-6736, 01/2019, Volume 393, Issue 10167, pp. 143 - 155
Journal Article